Citation

Mehler-Wex C, Kölch M. Dtsch Arztebl Ausg A 2008; 105(9): 149-155.

Copyright

(Copyright © 2008, Deutscher Ärzte-Verlag)

DOI

10.3238/arztebl.2008.0149

PMID

unavailable

Abstract

INTRODUCTION: Prevalence rates for depression in children and adolescents are estimated up to 8, 9%. Symptoms in this age group are different from those of depression in adults. Both neurobiological and psychosocial factors are involved in its development.

METHODS: Selective literature review.

RESULTS: Of note are both the high rate of spontaneous remissions in childhood (33%), and the high rate of depressions continuing into adulthood (80%). In addition far fewer evidence based treatments are available than for adults. Fluoxetine is currently the only medication licensed for use in children and adolescents for this indication. Tri- and tetracyclic antidepressants have not been shown in meta-analyses to be effective in children and adolescents. Most antidepressants lead to age related side effects, including attention deficit and in particular behavioural toxicity, which has to be taken seriously whereever there is a suicide risk.

DISCUSSION: The treatment of depression in childhood and adolescence should be based on multimodal interventions including psychotherapy, including cognitive behavioral therapy, which has proven effectiveness, psychosocial interventions and medications in severe cases. Patients with severe depression, especially suicidal minors, should be treated in patients units.

Language: de

Keywords

human; Depression; suicide; Suicide; psychotherapy; depression; childhood; adulthood; comorbidity; Mental disorder; review; risk; analgesic agent; anxiolytic agent; differential diagnosis; behavior disorder; citalopram; fluoxetine; fluvoxamine; mirtazapine; nefazodone; noradrenalin uptake inhibitor; paroxetine; serotonin uptake inhibitor; sertraline; tricyclic antidepressant agent; venlafaxine; social psychology; reboxetine; drug efficacy; attention deficit disorder; neurobiology; evidence based medicine; remission; tetracyclic antidepressant agent; Pediatric disease; Serotonin reuptake inhibitor